BioVaxys and Sona Nanotech Enter Research Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2025
0mins
Should l Buy ?
Source: PRnewswire
Collaboration Announcement: BioVaxys Technology Corp. and Sona Nanotech Inc. have entered a research agreement to develop new cancer therapies combining BioVaxys' DPX™ Immune Educating Platform with Sona's Targeted Hyperthermia Therapy, which utilizes infrared light and gold nanorod technology to treat solid tumors.
Research Focus and Potential: The collaboration aims to evaluate the immune-stimulating properties of the DPX platform alongside Sona's therapy, potentially leading to enhanced treatments for immunotherapy-resistant solid tumors, with studies conducted at Dalhousie University in Halifax.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
